Author of

• 31322

  +

  P2.11 - Screening and Early Detection (ID 178)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31330

    +

    P2.11-06 - Serum Proteomic Signature as a Potential Biomarker for Survival in Patients with NSCLC Receiving Immunotherapy (Now Available) (ID 86)

    10:15 - 18:15  |  Presenting Author(s): Won Bin Kim
    • Abstract
    • Slides

    Background
    

    The VeriStrat Test is a serum assay which uses a mass spectrometry (MS)-based proteomic signature derived from machine learning. It is currently used as a prognostic marker for patients with NSCLC receiving chemotherapy. However, little is known about its role for NSCLC patients receiving immune checkpoint inhibitors (ICIs).

    Method
    

    This is a retrospective study that includes 47 patients with advanced stage NSCLC without an activating EGFR mutation, who underwent the VeriStrat Test from 2016 to 2018. Spectra from blood samples were evaluated to assign patients into the VeriStrat ‘Good’ (VS-G) or VeriStrat ‘Poor’ (VS-P) risk group. The clinical outcomes of 32 patients who received programmed cell death 1(PD-1) inhibitors nivolumab or pembrolizumab were analyzed by the VeriStrat status.

    Result
    

    The VS-G group demonstrated significantly higher progression-free survival (PFS) and overall survival (OS) compared to the VS-P group among overall NSCLC patients regardless of treatment (median PFS of 7.1 vs. 4.2 months, p=0.013, and median OS, not reached vs. 17.2 months, p=0.012). Among NSCLC patients treated with ICIs, VS-G classification was associated with significantly increased PFS in comparison to VS-P classification (median PFS of 6.2 vs. 3.0 months, p=0.012), while the differences in OS trended towards significance (median OS, not reached vs. 16.5 months, p=0.076). Multivariate analyses showed that the VeriStrat status had a borderline significance (p=0.051) in predicting PFS in NSCLC patients treated with ICIs.

    

    Conclusion
    

    MS-based serum proteomic signature has a potential as a biomarker for survival outcome in NSCLC patients receiving immunotherapy.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.